Leerink Partnrs Issues Pessimistic Outlook for CLDX Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2029 earnings estimates for Celldex Therapeutics in a research report issued on Friday, May 9th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings of $6.20 per share for the year, down from their prior forecast of $6.62. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.08 million.

Other research analysts have also issued reports about the company. The Goldman Sachs Group dropped their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday. Morgan Stanley dropped their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 price target for the company. UBS Group lowered their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Down 6.1%

CLDX opened at $18.33 on Monday. The firm has a market capitalization of $1.22 billion, a P/E ratio of -7.13 and a beta of 1.39. The stock has a fifty day moving average of $18.99 and a 200-day moving average of $22.80. Celldex Therapeutics has a 12-month low of $14.40 and a 12-month high of $47.00.

Institutional Trading of Celldex Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth $38,919,000. Point72 Asset Management L.P. boosted its holdings in Celldex Therapeutics by 50.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after purchasing an additional 847,264 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after buying an additional 676,771 shares during the last quarter. Vestal Point Capital LP acquired a new position in Celldex Therapeutics during the fourth quarter worth $7,707,000. Finally, American Century Companies Inc. raised its holdings in Celldex Therapeutics by 46.5% during the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after buying an additional 193,093 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.